BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

93 related articles for article (PubMed ID: 14973301)

  • 1. Rheumatoid arthritis does not reduce the pharmacodynamic response to valsartan.
    Daneshtalab N; Lewanczuk RZ; Russell A; Jamali F
    J Clin Pharmacol; 2004 Mar; 44(3):245-52. PubMed ID: 14973301
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Drug-disease interactions: losartan effect is not downregulated by rheumatoid arthritis.
    Daneshtalab N; Lewanczuk RZ; Russell AS; Jamali F
    J Clin Pharmacol; 2006 Nov; 46(11):1344-55. PubMed ID: 17050800
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The effect of valsartan on the angiotensin II pressor response in healthy normotensive male subjects.
    Morgan JM; Palmisano M; Piraino A; Hirschhorn W; Spencer S; Prasad PP; Ortiz M; Lloyd P
    Clin Pharmacol Ther; 1997 Jan; 61(1):35-44. PubMed ID: 9024172
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Vildagliptin, a novel dipeptidyl peptidase IV inhibitor, has no pharmacokinetic interactions with the antihypertensive agents amlodipine, valsartan, and ramipril in healthy subjects.
    He YL; Ligueros-Saylan M; Sunkara G; Sabo R; Zhao C; Wang Y; Campestrini J; Pommier F; Dole K; Marion A; Dole WP; Howard D
    J Clin Pharmacol; 2008 Jan; 48(1):85-95. PubMed ID: 17986525
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Effects of angiotensin II on inflammation mediators in healthy subjects].
    Lottermoser K; Ulrich-Merzenich G; Vetter H; Düsing R
    Dtsch Med Wochenschr; 2003 Nov; 128(47):2470-5. PubMed ID: 14628252
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacokinetic and pharmacodynamic interaction of single doses of valsartan and atenolol.
    Czendlik CH; Sioufi A; Preiswerk G; Howald H
    Eur J Clin Pharmacol; 1997; 52(6):451-9. PubMed ID: 9342580
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of angiotensin II infusion with and without angiotensin II type 1 receptor blockade on nitric oxide metabolism and endothelin in human beings: a placebo-controlled study in healthy volunteers.
    Gossmann J; Burkhardt R; Harder S; Lenz T; Sedlmeyer A; Klinkhardt U; Haak T; Geiger H; Scheuermann EH
    Clin Pharmacol Ther; 2000 Nov; 68(5):501-9. PubMed ID: 11103753
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy and tolerability of combination therapy with valsartan plus hydrochlorothiazide compared with amlodipine monotherapy in hypertensive patients with other cardiovascular risk factors: the VAST study.
    Ruilope LM; Malacco E; Khder Y; Kandra A; Bönner G; Heintz D
    Clin Ther; 2005 May; 27(5):578-87. PubMed ID: 15978306
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effects of the angiotensin II type 1 receptor antagonist valsartan on the expression of superoxide dismutase in hypertensive patients.
    Yang HY; Kao PF; Chen TH; Tomlinson B; Ko WC; Chan P
    J Clin Pharmacol; 2007 Mar; 47(3):397-403. PubMed ID: 17322151
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacokinetics and pharmacodynamic effects of the angiotensin II antagonist valsartan at steady state in healthy, normotensive subjects.
    Müller P; Flesch G; de Gasparo M; Gasparini M; Howald H
    Eur J Clin Pharmacol; 1997; 52(6):441-9. PubMed ID: 9342579
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Reduction of QTc dispersion by the angiotensin II receptor blocker valsartan may be related to its anti-oxidative stress effect in patients with essential hypertension.
    Miyajima K; Minatoguchi S; Ito Y; Hukunishi M; Matsuno Y; Kakami M; Kawasaki M; Nishigaki K; Takemura G; Fujiwara H
    Hypertens Res; 2007 Apr; 30(4):307-13. PubMed ID: 17541209
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Hormonal and hemodynamic effects of aliskiren and valsartan and their combination in sodium-replete normotensive individuals.
    Azizi M; Ménard J; Bissery A; Guyene TT; Bura-Rivière A
    Clin J Am Soc Nephrol; 2007 Sep; 2(5):947-55. PubMed ID: 17702736
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Tolerability and blood pressure-lowering efficacy of the combination of amlodipine plus valsartan compared with lisinopril plus hydrochlorothiazide in adult patients with stage 2 hypertension.
    Poldermans D; Glazes R; Kargiannis S; Wernsing M; Kaczor J; Chiang YT; Yen J; Gamboa R; Fomina I
    Clin Ther; 2007 Feb; 29(2):279-89. PubMed ID: 17472820
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacodynamic and pharmacokinetic properties of an angiotensin II receptor antagonist--characterization by use of Schild regression technique in man.
    Breithaupt-Grögler K; Malerczyk C; Belz GG; Butzer R; Herrmann V; Stass H; Wensing G
    Int J Clin Pharmacol Ther; 1997 Oct; 35(10):434-41. PubMed ID: 9352392
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Single-pill combination of amlodipine and valsartan in the management of hypertension.
    Flack JM; Hilkert R
    Expert Opin Pharmacother; 2009 Aug; 10(12):1979-94. PubMed ID: 19606937
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmacokinetics of valsartan in patients with liver disease.
    Brookman LJ; Rolan PE; Benjamin IS; Palmer KR; Wyld PJ; Lloyd P; Flesch G; Waldmeier F; Sioufi A; Mullins F
    Clin Pharmacol Ther; 1997 Sep; 62(3):272-8. PubMed ID: 9333102
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Valsartan/hydrochlorothiazide: pharmacology and clinical efficacy.
    Kondrack R; Mohiuddin S
    Expert Opin Drug Metab Toxicol; 2009 Sep; 5(9):1125-34. PubMed ID: 19689218
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effects of valsartan and nifedipine coat-core on systemic arterial stiffness in hypertensive patients.
    Munakata M; Nagasaki A; Nunokawa T; Sakuma T; Kato H; Yoshinaga K; Toyota T
    Am J Hypertens; 2004 Nov; 17(11 Pt 1):1050-5. PubMed ID: 15533733
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The angiotensin II receptor antagonist valsartan enhances lipoprotein lipase mass in preheparin serum in type 2 diabetes with hypertension.
    Saiki A; Ohira M; Endo K; Koide N; Oyama T; Murano T; Miyashita Y; Shirai K
    Diabetes Res Clin Pract; 2006 Dec; 74(3):242-8. PubMed ID: 16713009
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The angiotensin II receptor antagonist valsartan inhibits endothelin 1-induced vasoconstriction in the skin microcirculation in humans in vivo: influence of the G-protein beta3 subunit (GNB3) C825T polymorphism.
    Mitchell A; Rushentsova U; Siffert W; Philipp T; Wenzel RR
    Clin Pharmacol Ther; 2006 Mar; 79(3):274-81. PubMed ID: 16513451
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.